Table 2 The relationship between PGC mRNA expression and the clinicopathological characteristics of breast cancer
From: The relationship between pepsinogen C and gastric carcinogenesis: a transgene and population study
Clinicopathological features | Variable | Low expression | High expression | P |
|---|---|---|---|---|
Age, n (%) | ≦60 | 292 (27%) | 309 (28.5%) | 0.345 |
 > 60 | 249 (23%) | 233 (21.5%) | ||
T stage, n (%) | T1 | 137 (12.7%) | 140 (13%) | 0.537 |
T2 | 321 (29.7%) | 308 (28.5%) | ||
T3 | 62 (5.7%) | 77 (7.1%) | ||
T4 | 19 (1.8%) | 16 (1.5%) | ||
N stage, n (%) | N0 | 259 (24.3%) | 255 (24%) | 0.136 |
N1 | 177 (16.6%) | 181 (17%) | ||
N2 | 64 (6%) | 52 (4.9%) | ||
N3 | 29 (2.7%) | 47 (4.4%) | ||
M stage, n (%) | M0 | 456 (49.5%) | 446 (48.4%) | 0.111 |
M1 | 6 (0.7%) | 14 (1.5%) | ||
Pathologic stage, n (%) | Stage I | 91 (8.6%) | 90 (8.5%) | 0.304 |
Stage II | 311 (29.3%) | 308 (29.1%) | ||
Stage III | 118 (11.1%) | 124 (11.7%) | ||
Stage IV | 5 (0.5%) | 13 (1.2%) | ||
Histological type, n (%) | IDC | 417 (42.7%) | 355 (36.3%) |  < 0.001 |
ILC | 71 (7.3%) | 134 (13.7%) | ||
PR status, n (%) | Negative | 200 (19.3%) | 142 (13.7%) |  < 0.001 |
Indeterminate | 2 (0.2%) | 2 (0.2%) | ||
Positive | 313 (30.3%) | 375 (36.3%) | ||
ER status, n (%) | Negative | 146 (14.1%) | 94 (9.1%) |  < 0.001 |
Indeterminate | 2 (0.2%) | 0 (0%) | ||
Positive | 367 (35.5%) | 426 (41.2%) | ||
HER2 status, n (%) | Negative | 286 (39.3%) | 272 (37.4%) | 0.843 |
Indeterminate | 7 (1%) | 5 (0.7%) | ||
Positive | 83 (11.4%) | 74 (10.2%) | ||
PAM50, n (%) | Normal | 16 (1.5%) | 24 (2.2%) |  < 0.001 |
Luminal A | 244 (22.5%) | 318 (29.4%) | ||
Luminal B | 108 (10%) | 96 (8.9%) | ||
Her2 +  | 32 (3%) | 50 (4.6%) | ||
Basal | 141 (13%) | 54 (5%) |